Hanall Biopharma Co., Ltd.

Hanall Pharmaceutical Company, Ltd.

Hanall Pharmaceuticals, Co. Ltd

Rene Gantier

Lila Drittanti

Thierry Guyon

Manuel Vega

Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.

Protease resistant modified erythropoietin polypeptides

Protease resistant modified interferon-beta polypeptides, and pharmaceutical compositions containing such modified interferon-beta polypeptides are provided. The modified interferon-beta polypeptides contain amino acid substitutions that confer increased resistance to proteolysis over unmodified IFN beta cytokine molecules. The present invention provides for pharmaceutical formulations suitable for oral, nasal and pulmonary administration, and the use of such formulations in the treatment of disease.

Protease resistant modified IFN beta polypeptides and their use in treating diseases

Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.

Protease resistant modified interferon-beta polypeptides

Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.

Interferon-&#x3b2; mutants with increased anti-proliferative activity

Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Protease resistant interferon beta mutants

Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.

Growing community of inventors

Elancourt, France

Rene Gantier